Download Data Safety Monitoring Plan - Kennesaw State University | Office of

Data Safety Monitoring Plan
The NIH Data and Safety Monitoring Policy is described and referenced in Part II Section 5.3.
If the proposed research includes a clinical trial (See definition of “clinical trial” under Part III Section 3), create
a document entitled "Data and Safety Monitoring Plan." For all clinical trials, NIH requires a data and safety
monitoring plan (DSMP) that is commensurate with the risks of the trial and its size and complexity. In this
attachment, you must provide a description of the DSMP that you are proposing to establish for each clinical
trial proposed, including:




The overall framework for safety monitoring and what information will be monitored.
The frequency of monitoring, including any plans for interim analysis and stopping rules (if applicable).
The process by which Adverse Events (AEs), including Serious Adverse Events (SAEs) such as
deaths, hospitalizations, and life threatening events and Unanticipated Problems (Ups), will be
managed and reported as required to the Institutional Review Board (IRB), the person or group
responsible for monitoring, the funding IC, the NIH Office of Biotechnology Activities (OBA;
http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines) , and the Food and Drug
Administration (FDA; http://www.fda.gov/).
The individual(s) or group that will be responsible for trial monitoring and advising the appointing entity.
Because the monitoring plan will depend on potential risks, complexity, and the nature of the trial, a
number of options for monitoring are possible. These include, but are not limited to, monitoring by a:
o PD/PI: While the PD/PI must ensure that the trial is conducted according to the protocol, in
some cases (e.g., low risk trials, not blinded), it may be acceptable for the PD/PI to also be
responsible for carrying out the DSMP.
o Independent safety monitor/Designated medical monitor: a physician or other expert who is
independent of the study.
o Independent Monitoring Committee or Safety Monitoring Committee: A small group of
independent investigators and biostatisticians.
o Data and Safety Monitoring Board (DSMB): a formal independent board of experts including
investigators and biostatisticians. As noted in Part II Section 5.3, NIH requires the establishment
of DSMBs for multi-site clinical trials involving interventions that entail potential risk to the
Supplemental Grant Application Instructions II-11 participants, and generally for Phase III
clinical trials. Although Phase I and Phase II clinical trials may also need DSMBs, smaller
clinical trials may not require this oversight format, and alternative monitoring plans may be
appropriate.
 If a DSMB is used, please describe the general composition of the Board without naming
specific individuals.